Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EBOVmembrinteract

Financiado

Cerrado

Molecular mechanisms behind filovirus entry and egress: the role of viral glycop...

Molecular mechanisms behind filovirus entry and egress: the role of viral glycoprotein glycosylation Filoviruses are amongst the most dangerous human pathogens. They pose a great health concern, due to a growing number of emerging species, that vary in tropism and pathogenicity. In my work, I aim at establishing a correlation bet... ver más

30/09/2026

UMEA UNIVERSITET

207K€

Presupuesto del proyecto: 207K€

Líder del proyecto

UMEA UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-25

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UMEA UNIVERSITET

206.89K€ | Lider

Proyectos interesantes

BRACE

Medical Technol...

Applied Physics

166K€ Cerrado

ARENAVIRUS

Medical Technol...

Applied Physics

183K€ Cerrado

VIRUS ENTRY

Medical Technol...

Applied Physics

4M€ Cerrado

BFU2009-08085

Medical Technol...

Applied Physics

100K€ Cerrado

CoVentry

Medical Technol...

Applied Physics

192K€ Cerrado

KGBVIFEF

Medical Technol...

Applied Physics

183K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 30 meses Fecha Inicio: 2024-03-25
Fecha Fin: 2026-09-30

Líder del proyecto

UMEA UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 207K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Filoviruses are amongst the most dangerous human pathogens. They pose a great health concern, due to a growing number of emerging species, that vary in tropism and pathogenicity. In my work, I aim at establishing a correlation between filoviruses pathogenicity, the characteristics of their interaction with the cell membrane and their entry and egress potential. In this context, I hypothesize that viral carbohydrates are key in modulating these processes. For this study, I have selected a number of filovirus species, distinct in their pathogenicity for humans. I will use a transcription and replication competent virus like particle system (trVLP) as a BSL-2 virus model, and will produce particles presenting the glycoproteins (GP) from the different filovirus species of interest. GP is the sole glycoprotein found on the virus surface and is crucial for filovirus attachment and entry. Using an interdisciplinary approach combining virology, biophysics and glycobiology, I will first carry out infection assays, to characterize the entry and egress potential of the different particles. I will further investigate the role of two key attachment molecules, heparan sulfate and DC-SIGN in modulating those processes. This will be achieved first on the cellular level, and then on the molecular level, using single molecule force spectroscopy to look at the characteristics of individual ligand-receptor bonds. Extensive glycomic analysis, amongst other via mass spectrometry, will further address the hypothesis that the GPs glycan profile plays a key role in determining the behaviour of the different filoviruses. Taken together, I will provide a comprehensive description of the influence of the different GPs in viral entry and egress, on the molecular, functional, and biological levels. Such insights will without doubt be key to the development of efficient and broad-spectrum antivirals.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores